Correlation Between Hookipa Pharma and Neurocrine Biosciences

Can any of the company-specific risk be diversified away by investing in both Hookipa Pharma and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hookipa Pharma and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hookipa Pharma and Neurocrine Biosciences, you can compare the effects of market volatilities on Hookipa Pharma and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hookipa Pharma with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hookipa Pharma and Neurocrine Biosciences.

Diversification Opportunities for Hookipa Pharma and Neurocrine Biosciences

-0.83

Correlation Coefficient

Hookipa Pharma  Neurocrine Biosciences

Pay attention - limited upside

The 3 months correlation between Hookipa and Neurocrine is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding Hookipa Pharma and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Hookipa Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hookipa Pharma are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Hookipa Pharma i.e., Hookipa Pharma and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Hookipa Pharma and Neurocrine Biosciences

Given the investment horizon of 90 days Hookipa Pharma is expected to under-perform the Neurocrine Biosciences. In addition to that, Hookipa Pharma is 1.85 times more volatile than Neurocrine Biosciences. It trades about -0.18 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about 0.01 per unit of volatility. If you would invest  13,767  in Neurocrine Biosciences on September 26, 2024 and sell it today you would lose (114.00) from holding Neurocrine Biosciences or give up 0.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Hookipa Pharma  vs.  Neurocrine Biosciences

Hookipa Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Neurocrine Biosciences

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Hookipa Pharma and Neurocrine Biosciences

The main advantage of trading using opposite Hookipa Pharma and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hookipa Pharma position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.

The idea behind Hookipa Pharma and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.